Mazdutide
IBI362 · GLP-1/GCGR dual agonist · Oxyntomodulin analogue
A once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics, in Phase 3 trials for obesity and type 2 diabetes with up to 18% body weight loss.
Half-Life
~5-6 days (once-weekly dosing)
MW
~3.8 kDa (estimated)
Amino Acids
30 AA
Evidence
Clinical
Regulatory Status
Phase 3 clinical trials in China (GLORY program, Innovent Biologics). NDA filing expected. Not yet approved anywhere. IND discussions ongoing for US/EU.
In Plain English
A next-generation weight loss peptide that activates two receptors at once: the GLP-1 receptor (reduces appetite and blood sugar) AND the glucagon receptor (boosts fat burning and metabolism). Based on a natural gut hormone called oxyntomodulin. In clinical trials it produced up to 18% body weight loss — potentially stronger than semaglutide alone.
Overview
Mazdutide (IBI362) is a long-acting dual agonist developed by Innovent Biologics (China) that simultaneously activates GLP-1 receptors (GLP-1R) and glucagon receptors (GCGR). This dual mechanism provides both glucose-lowering (via GLP-1R) and metabolic rate-increasing/lipid-mobilizing (via GCGR) effects, potentially superior weight loss compared to GLP-1-only agonists like semaglutide. It is based on an oxyntomodulin (OXM) scaffold — a natural gut peptide that activates both receptors. In Phase 3 clinical trials in China for obesity and type 2 diabetes, it has demonstrated significant weight reduction up to 18% of body weight. Represents the next generation of GLP-1-based obesity therapies.
Common Formats
- Pre-filled syringe (clinical trial)
- Injectable (subcutaneous, once weekly)
Storage Notes
Clinical formulation: 2-8°C. Protect from freezing and light. Research powder: -20°C.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Mazdutide.
Research Sources
(3 vendors)For research use only. No affiliation or endorsement implied.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.
Survodutide
A once-weekly GLP-1/glucagon receptor dual agonist by Boehringer Ingelheim in Phase 2/3 trials for NASH/MASH, obesity, and metabolic disease.
Liraglutide
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.